Where Will AbbVie Be in 5 Years?
A lot has changed for (NYSE: ABBV) over the past five years. Notably, the biotech company's Humira, once its biggest growth driver and the world's best-selling drug, lost patent exclusivity in the U.S. in 2023. Despite that setback, AbbVie has produced solid returns over the last half a decade.
But can the drugmaker maintain that momentum through 2031? Let's find out how things might unfold for AbbVie over the next five years.
Image source: Getty Images.
Source Fool.com
AbbVie Inc. Aktie
200,50 €
1,63 %
Volle Unterstützung für AbbVie Inc.: Nur Buy-Einschätzungen, keine Sell-Einschätzungen.
Für AbbVie Inc. sieht die Community ein leicht positives Kursziel von 210 €, verglichen mit dem aktuellen Kurs von 200.5 €.
